The first human candidate vaccine created from the KISIMA platform, ATP128, is one such chimeric recombinant protein vaccine in which the Mad consists of three antigens selected because of their overexpression in a large percentage of Colorectal Cancer (CRC) tissues: carcinoembryonic antigen (CEA), Survivin, and Achaete-scute complex homolog 2 (ASCL2) [3]. This evidence concerns the gene CEACAM5 and colorectal carcinoma.